



MedAdvisor Limited
ACN 145 327 617
Level 2, 971 Burke Road
Camberwell Vic 3124
mymedadvisor.com/investors

ASX RELEASE (ASX: MDR)

MedAdvisor further strengthens board with appointment of highly experienced US health tech executive Kevin Hutchinson

Key highlights:

- **Kevin Hutchinson appointed as non-executive director (US based) effective 23 November 2022. Mr. Hutchison is a highly experienced healthcare technology executive with a track record of successfully building innovative health tech companies in the US**
- **Robert Read to step down from his role as an Executive Director on 30 November 2022**

Melbourne, Australia, 19 October, 2022 – Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) (ASX: MDR) is pleased to announce the appointment of Kevin Hutchinson as a non-executive director effective 23 November 2022.

With over 35 years' experience in technology, Mr. Hutchinson has extensive leadership experience and a successful track record in the development and deployment of innovative technology companies in the healthcare sector in the US. He is currently working with Abundant Venture Partners to incubate a company, AXL Health, focused on providing precision patient intelligence to increase health coverage, reduce health disparities, and improve the management of chronic disease. Previously, Mr. Hutchison served in multiple senior roles within healthcare technology start-ups and growth stage ventures, including being the founding CEO of Surescripts, the first nation-wide SaaS-based health information network company in the US.

Highly regarded for his digital innovation expertise in the healthcare sector in the US, Mr. Hutchison's extensive experience and achievements include leading teams that:

- developed one of the first electronic medical record solutions; delivered a mobile app for providers to close gaps in care; and built and grew the largest health intelligence sharing network that serves the US market nationally to prescribe medications electronically

- being appointed by two US Presidential administrations to advise on national health IT strategies
- serving on seven boards including health technology businesses Eon Health, Kit Check, SourceMed, dbMotion, Prematics, Surescripts and Apervita.

Mr. Hutchison holds a Bachelor's degree in Business Administration from the University of Oklahoma and was a recipient of the 2015 Distinguished Alumni Award.

Commenting on Mr. Hutchinson's appointment to MedAdvisor's Board, Chair Linda Jenkinson said: "Kevin's appointment as a non-executive Director to MedAdvisor's Board will bring valuable insight and added guidance as we expand our digital reach and continue to invest in technology innovation, particularly in the US. We are delighted that Kevin has agreed to join the Board, and I am confident that his proven breadth of experience successfully developing and expanding innovative health tech businesses in the US will further add to the Board's skill set and support management in delivering on our key strategic priorities."

Commenting on his appointment as a non-executive director of MedAdvisor, Mr. Hutchinson said: "I have a strong passion to build and grow companies that deliver innovative healthcare services via disruptive and revolutionary technology. MedAdvisor, with its unique tech platform and passion for innovation, has an exciting future and I am delighted that I will be able to join and contribute to MedAdvisor's strategic growth ambitions."

Having provided continuity and support to the Company through a transition period following the appointment of Rick Ratliff as CEO and Managing Director, current Executive Director Robert Read will be stepping down from the Board and his role at MedAdvisor on 30 November 2022 and will not be seeking re-election at the upcoming AGM.

Commenting on Mr. Read's departure from MedAdvisor, Mrs. Jenkinson said: "On behalf of the Board, I'd like to thank Rob for his leadership and contribution to MedAdvisor's growth over the past seven years, and for facilitating a smooth transition to our new CEO, Rick Ratliff. With the technology, network and platform in place to drive strong growth, with a new leadership team appointed, MedAdvisor is well placed to deliver on the potential that lies ahead for the business in our core markets."

MedAdvisor's 2022 AGM is being held on 30 November 2022.

- ENDS -

This document has been authorised for release by the Chair of MedAdvisor Limited.

For more information:

Company

Rick Ratliff, CEO & Managing Director
corporate@medadvisor.com.au

Investors

Ronn Bechler
ronn.bechler@automicgroup.com.au
 +61 400 009 774

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.9 million patients through more than 90% of Australian pharmacies. MedAdvisor is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors